Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer

Dr Jacob Sands - Dana-Farber Cancer Institute, Boston, USA
Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer ( Dr Jacob Sands - Dana-Farber Cancer Institute, Boston, USA )
26 Oct 2026

ESMO 2026: Highlights and analysis

Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2026: Highlights and analysis ( Prof Bishal Gyawali - Queen's University, Kingston, Canada )
26 Oct 2026

Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer

Dr Meredith Pelster - Sarah Cannon Research Institute, Nashville, USA
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer ( Dr Meredith Pelster - Sarah Cannon Research Institute, Nashville, USA )
26 Oct 2026

Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer

Dr Joana Ribeiro - Gustave Roussy, Villejuif, France
Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer ( Dr Joana Ribeiro - Gustave Roussy, Villejuif, France )
25 Oct 2026

Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

Prof Georgina Long - Melanoma Institute Australia, Sydney, Australia
Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma ( Prof Georgina Long - Melanoma Institute Australia, Sydney, Australia )
25 Oct 2026

ESMO 2026: Advances in NMIBC and MIBC

Dr Bernadett Szabados, Prof Andrea Necchi, Dr Félix Guerrero-Ramos and Prof Yohann Loriot
ESMO 2026: Advances in NMIBC and MIBC ( Dr Bernadett Szabados, Prof Andrea Necchi, Dr Félix Guerrero-Ramos and Prof Yohann Loriot )
25 Oct 2026

UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer

Dr Trine Jakobi Nøttrup - Copenhagen University Hospital, Copenhagen, Denmark
UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer ( Dr Trine Jakobi Nøttrup - Copenhagen University Hospital, Copenhagen, Denmark )
24 Oct 2026

HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma

Dr Nikhil Khushalani - Moffitt Cancer Center, Tampa, USA
HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma ( Dr Nikhil Khushalani - Moffitt Cancer Center, Tampa, USA )
24 Oct 2026

Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer

Prof Eileen O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA
Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer ( Prof Eileen O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA )
24 Oct 2026

TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer

Prof Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA
TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer ( Prof Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA )
24 Oct 2026

Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer

Dr Randy Sweis - University of Chicago, Chicago, USA
Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer ( Dr Randy Sweis - University of Chicago, Chicago, USA )
24 Oct 2026

Tarlatamab's role in SCLC

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Tarlatamab's role in SCLC ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
15 Oct 2026